Nesina (Alogliptin)

Save 75% over generic Nesina in the USA with insulinhub and over 80% on the brand version.

Nesina brand medicine goes by the trade name Vipidia in the United Kingdom.

Information About Nesina (Alogliptin)

Nesina is the brand name for alogliptin, an oral medication used to manage type 2 diabetes. Alogliptin belongs to a class of drugs known as DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). It works by increasing the levels of incretin hormones in the body, which help to regulate blood sugar (glucose) levels. Specifically, alogliptin helps enhance insulin secretion after meals and reduces the amount of glucose produced by the liver, thereby lowering blood glucose levels in people with type 2 diabetes.

Nesina is typically prescribed when lifestyle changes (such as diet and exercise) alone are not sufficient to control blood sugar levels. It is often used in combination with other anti-diabetic medications to improve blood sugar control.

Product Highlights

• Nesina (alogliptin) is primarily indicated for the management of type 2 diabetes and is used:
• To improve blood sugar control in patients with type 2 diabetes who cannot achieve adequate glucose control with lifestyle changes (diet and exercise) alone.
• When used alongside other medications (such as metformin, sulfonylureas, or insulin), Nesina helps to improve overall blood glucose control in individuals with type 2 diabetes.
• It is not used for type 1 diabetes or for the treatment of diabetic ketoacidosis.

Key Ingredient

• Alogliptin

Key Benefits

• Nesina helps to regulate blood glucose levels by stimulating insulin secretion after meals and inhibiting glucose production by the liver.
• Alogliptin is generally well-tolerated, with a lower risk of causing hypoglycemia (low blood sugar) when used alone, as it does not directly stimulate insulin release in the absence of elevated blood glucose.
• Nesina is taken once daily, which makes it easy for patients to incorporate into their daily routine.
• It can be used in combination with other anti-diabetic medications, offering flexibility in treatment plans for better blood sugar management.
• Unlike some other diabetes medications, Nesina has a neutral effect on body weight, making it an appealing option for people looking to manage their weight alongside diabetes.

Direction of Use

• The usual recommended dose of Nesina is 25 mg once daily, regardless of meals.

Administration:

• Take the tablet by mouth with or without food.
• Swallow the tablet whole with water.
• If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not take an extra dose to make up for a missed one.
• The dose may need to be adjusted in patients with kidney impairment, particularly those with severe renal impairment (e.g., CrCl < 30 mL/min), as alogliptin is eliminated by the kidneys.

Safety Concerns

• There have been reports of acute pancreatitis (inflammation of the pancreas) in patients taking DPP-4 inhibitors like alogliptin. If you experience unexplained severe abdominal pain, contact your healthcare provider immediately.
• Nesina should be used with caution in patients with impaired kidney function. Dose adjustments are necessary for patients with mild-to-moderate renal impairment (CrCl < 60 mL/min), and the medication is contraindicated in those with severe renal impairment (CrCl < 30 mL/min).
• Alogliptin can cause allergic reactions, including angioedema (swelling of deeper layers of the skin, especially around the eyes and lips). If you notice signs of an allergic reaction, such as swelling or difficulty breathing, seek medical help immediately.
• While Nesina alone does not typically cause low blood sugar, it may increase the risk of hypoglycemia when combined with other anti-diabetic medications that can lower blood sugar, such as insulin or sulfonylureas. Close monitoring of blood glucose is recommended when used in combination therapy.
• There have been some concerns about an increased risk of heart failure with certain DPP-4 inhibitors, including alogliptin, particularly in patients with existing heart disease. Monitor for signs of heart failure (e.g., shortness of breath, swelling in the legs) during treatment.

Avoid Nesina (Alogliptin) If

• Do not use Nesina if you are allergic to alogliptin or any of the other ingredients in the medication. Symptoms of an allergic reaction may include a rash, swelling, or trouble breathing.
• Nesina is contraindicated in patients with severe kidney problems (CrCl < 30 mL/min) because it is primarily eliminated by the kidneys. In such cases, a different diabetes medication should be considered.
• Avoid using Nesina if you have a history of pancreatitis or if you experience unexplained severe abdominal pain while taking the medication.
• The safety of Nesina during pregnancy and breastfeeding has not been fully determined. It should only be used during pregnancy if clearly needed, and the potential benefits and risks should be discussed with a healthcare provider. It is not known whether alogliptin passes into breast milk, so it is recommended to avoid breastfeeding while using this medication.
• Avoid use if you have a history of severe allergic reactions to any other DPP-4 inhibitors or related medications.